Back to Newsroom

Conatus Pharmaceuticals Announces Selection of Late-Breaking Oral Presentation as Noteworthy Abstract to be Highlighted in AASLD President’s Press Conference at AASLD Annual Meeting

SAN DIEGO, Nov. 14, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today that the company’s late-breaking oral presentation at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco November 13-17, 2015, was one of 16 selected as key abstracts (from among the 2,299 abstracts accepted for presentation at The Liver Meeting®) to be highlighted by Gyongy Szabo, M.D., Ph.D., in the AASLD President’s press conference at 4:00 p.m. PST today.

The late-breaking presentation (#LB6), entitled “Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension,” will be delivered in Room 3000 of the Moscone West Convention Center at 4:15 p.m. PST on Monday by lead author Guadalupe Garcia-Tsao, M.D., a principal investigator in the trial and Professor of Medicine (Digestive Diseases) at Yale University Medical School; Chief, Digestive Diseases, VA-CT Healthcare System; and Director, Clinical and Translational Core, Yale Liver Center.

Click here to read more